✦ LIBER ✦

Low-dose risperidone reduces burden of Alzheimer’s disease

Book ID: 120875729
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 1997
Weight: 187 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-199711180-00038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Donepezil reduces high cost burden of Al

Donepezil reduces high cost burden of Alzheimer's disease

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 139 KB

Donepezil reduces high cost burden of Al

Donepezil reduces high cost burden of Alzheimer's disease

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 136 KB

ERT reduces risk of Alzheimer’s disease

ERT reduces risk of Alzheimer’s disease …

📂 Article 📅 1997 🏛 Adis International Limited (now part of Wolters Kl ⚖ 185 KB

Forecasting the global burden of Alzheim

Forecasting the global burden of Alzheimer’s disease

✍ Ron Brookmeyer; Elizabeth Johnson; Kathryn Ziegler-Graham; H. Michael Arrighi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Low dose, high dose, or no dose: better

Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease

✍ Ritchie, C.W.; Zhinchin, G. 📂 Article 📅 2013 🏛 Cambridge University Press 🌐 English ⚖ 74 KB

Peripherally expressed neprilysin reduce

Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease

✍ Hanjun Guan; Yinxing Liu; Abigail Daily; Sara Police; Myung-Hee Kim; Salvatore O 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

## Abstract A number of therapeutic strategies for treating Alzheimer's disease have focused on reducing amyloid burden in the brain. Among these approaches, the expression of amyloid β peptide (Aβ)‐degrading enzymes in the brain has been shown to be effective but to date not practical for treating